Lifestyle modification in patients with non-erosive reflux disease and overweight or obesity


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Obesity and gastroesophageal reflux disease are comorbid pathologies. A significant proportion of patients with non-erosive gastroesophageal reflux disease (NERD) have failed standard acid-suppressive therapy. The effectiveness of weight loss interventions and the effectiveness of acid suppression therapy has not been compared in patients with NERD and obesity. Objective. Comparison of the effectiveness of lifestyle changes (diet therapy, intensification of physical activity) and traditional therapy with proton pump inhibitors (PPIs) in overweight or obese patients with non-erosive reflux disease (NERD). Methods. The randomized clinical trial involved 30 patients with NERD, 12 (40%) men and 18 (60%) women of middle age, median age 51.5 (45; 62) years. 17(56.66%) patients were overweight, 13 (43.33%) - obese, and 27(90%) - with abdominal obesity. Patients were randomized into two groups: control group - 15 patients who received initial therapy with omeprazole 20 mg 1 time per day for 4 week, then maintenance therapy with omeprazole 10 mg 1 time per day for 5 months; intervention group - 15 patients who participated in the program for the correction of eating behavior for 6 months and received only initial therapy with omeprazole 10 mg 1 time per day for 4 weeks. The follow-up duration was 6 months. The effectiveness of the two treatments was compared by assessing the symptoms of gastroesophageal reflux disease, 24-hour pH-impedancemetry, levels of anxiety, depression, and quality of life. Results. At 1, 3, and 6 months, standard and experimental treatments had similar effects on heartburn and regurgitation symptoms. At the same time, by the sixth month of treatment, in the group of correction of eating behavior, personal anxiety was significantly lower, the quality of life according to the vitality scale of and the role-emotional scale was higher; 24-hour pH-impedancemetry revealed a lower total number of gastroesophageal refluxes (GERs), acid GERs, proximal acid GERs, less % of the time with pH <4. Conclusion. The study demonstrated the benefit of lifestyle modification over traditional PPI therapy in overweight or obese patients with NERD. Eating behavior modification and weight loss are similar to PPI therapy in terms of influencing the main symptoms of gastroesophageal reflux disease (heartburn and regurgitation), while improving upper gastrointestinal motility, reducing the number of distal and proximal acid GERs.

Full Text

Restricted Access

About the authors

Sergey V. Tikhonov

North-Western State Medical University n.a. I.I. Mechnikov

Email: sergeyvt2702@gmail.com
Cand. Sci. (Med.), Associate Professor at the Department of Internal Medicine, Clinical Pharmacology and Nephrology

V. I Simanenkov

North-Western State Medical University n.a. I.I. Mechnikov

N. V Bakulina

North-Western State Medical University n.a. I.I. Mechnikov

N. B Lischuk

North-Western State Medical University n.a. I.I. Mechnikov

References

  1. Vakil N., van Zanten S.V., Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J. Gastroenterol. 2006;101(8):1900-43.
  2. Katz P.O., Gerson L.B., Vela M.F. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J. Gastroenterol. 2013;108:308-28. doi: 10.1038/ajg.2012.444.
  3. El-Serag H.B., Sweet S., Winchester C.C., et al. Update on the epidemiology of gastrooesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-80. Doi: 10.1136/ gutjnl-2012-304269.
  4. Лазебник Л.Б., Машарова А.А., Бордин Д.С. и др. Результаты многоцентрового исследования «Эпидемиология гастроэзофагеальной рефлюксной болезни в России» («МЭГРЭ»). Терапевтический архив. 2011;1:5-50.
  5. Vakil N., van Zanten S.V., Kahrilas P., Den, J. & Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J. Gastroenterol. 2006;101:1900-20. doi: 10.1111/j.1572-0241.2006.00630.x.
  6. Modlin I.M. et al. Diagnosis and management of non-erosive reflux disease - The Vevey NERD Consensus Group. Digestion. 2009;80:74-88. doi: 10.1159/000219365.
  7. Sontag S.J., Sonnenberg A., Schnell T.G. et al. The long-term natural history of gastroesophageal reflux disease. J. Clin Gastroenterol. 2006;40(5):398-404. doi: 10.1097/00004836-200605000-00007.
  8. Agrawal A., Castell D. GERD is chronic but not progressive. J. Clin Gastroenterol. 2006;40(5):374-75. doi: 10.1097/00004836-200605000-00002.
  9. Fass R.,Ofman J. Gastroesophagealrefluxdisease-should we adopt a new conceptual framework? Am J. Gastroenterol. 2002;97:1901-09. doi: 10.1111/j.1572-0241.2002.05912.x.
  10. Ronkainen J., Aro P., Storskrubb T., et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J. Gastroenterol. 2005;40(3):275-85. doi: 10.1080/00365520510011579.
  11. Zagari R.M., Fuccio L., Wallander M.A. et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57:1354-59. Doi: 10.1136/ gut.2007.145177.
  12. Лищук Н.Б., Симаненков В.И., Тихонов С.В. Дифференцированная терапия «некислых» форм гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2017;04:57-63.
  13. Тихонов С.В., Симаненков В.И., Бакулина Н.В. и др. Мультитаргетная терапия у пациентов с ГЭРБ и ожирением. Медицинский алфавит. 2021;(6):8-13.
  14. Savarino E., Zentilin P., Marabotto E., et al. Overweight is a risk factor for both erosive and non-erosive reflux disease. Dig Liver Dis. 2011;43(12):940-45. Doi: 10.1016/j. dld.2011.07.014.
  15. El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008;53(9):2307-12. doi: 10.1007/s10620-008-0413-9.
  16. El-Serag H.B., Hashmi A., Garcia J., et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut. 2013. doi: 10.1136/gutjnl-2012-304189.
  17. Маев И.В., Бакулин И.Г., Бордин Д.С. и др. Клинико-эндоскопические характеристики ГЭРБ у пациентов с ожирением. Эффективная фармакотерапия. 2021;17(4):12-20. doi: 10.33978/2307-35862021-17-4-12-20.
  18. Suter M., Dorta G., Giusti V., et al. Gastroesophageal reflux and esophageal motility disorders in morbidly obese patients. Obes Surg. 2004;14(7):959-66. doi: 10.33978/23073586-2021-17-4-12-20.
  19. Koppman J.S., Poggi L., Szomstein S., et al. Esophageal motility disorders in the morbidly obese population. Surg Endosc. 2007;21(5):761-64. doi: 10.1007/s00464-006-9102-y.
  20. Ayazi S., Hagen J., Chan L., et al. Obesity and gastroesophageal reflux: quantifying the association between body mass index, esophageal acid exposure, and lower esophageal sphincter status in a large series of patients with reflux symptoms. J. Gastrointest Surg. 2009;13(8):1440-47. doi: 10.1007/s11605-009-0930-7.
  21. Kelesidis I., Kelesidis T., Mantzoros C.S. Adiponectin and cancer: a systematic review. Br J. Cancer. 2006;94(9):1221-25 Doi: 10.1038/ sj.bjc.6603051.
  22. Rubenstein J.H., Dahlkemper A., Kao J.Y., et al. A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J. Gastroenterol. 2008;103(6):1358-64. doi: 10.1111/j.1572-0241.2008.01823.x.
  23. Kendall B.J., Macdonald G.A., Hayward N.K., et al. Leptin and the risk of Barrett's oesophagus. Gut. 2008;57(4):448-54. Doi: 10.1136/ gut.2007.131243.
  24. WHO (2020), Obesity and overweight. URL: https://www.who.int/news-room/fact-sheets/ detail/obesity-and-overweight.
  25. Симаненков В.И., Тихонов С.В., Лищук Н.Б. Гастроэзофагеальная рефлюксная болезнь и ожирение. Кто виноват и что делать? Медицинский алфавит 2017;27:5-11.
  26. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. Melbourne (Australia): National Health and Medical Research Council. 2013 0ct;202. (NHMRC, Australia, 2013).
  27. Kim K.J., Lee B.S. Central Obesity as a Risk Factor for Non-Erosive Reflux Disease. Yonsei Med J. 2017;58(4):743-748. Doi: 10.3349/ ymj.2017.58.4.743.
  28. Ness-Jensen E., Lindam A., Lagergren J., et al. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J. Gastroenterol. 2013; 108(3):376-82. Doi: 10.1038/ ajg.2012.466.
  29. Singh M., Lee J., Gupta N., et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity (Silver Spring) 2013;21(2):284- 90. doi: 10.1002/oby.20279.
  30. Richter P., Werner J., Heerlein A., et al. On the validity of the Beck Depression Inventory. A review. Psychopathology. 1998;31(3):160-68. doi: 10.1159/000066239.
  31. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине. 2-е изд. Под ред. акад. РАМН Ю.Л. Шевченко. М.: ЗАО «ОЛМА Медиа Групп. 2007. 157-67 p.
  32. Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey. Manual and interpretation guide. The Health Institute, New England Medical Center. Boston, Mass. 1993. URL: http://www.sf-36.org/nbscalc/index.shtml
  33. Шляхто Е.В., Недогода С.В., Конради А.О. и др. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний (национальные клинические рекомендации). Санкт-Петербург, 2017.164 с.URL: httpsy/sccrdio.ruucontent/Guideiines/projecc/ Ozhirenie_klln_rek_psoek.pdf

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies